Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation

Transplantation Proceedings

Volumn 45, Issue 6, 2013, Pages 2331-2336

  Guillaud, O ^a   Gurram, K C ^a   Puglia, M ^a   Lilly, L ^a   Adeyi, O ^a   Renner, E L ^a   Selzner, N ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ENALAPRIL; FOSINOPRIL; PERINDOPRIL; RAMIPRIL;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DONOR; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIVIRAL AGENTS; BIOPSY; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882256538     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2013.01.067     Document Type: Article

References (36)

1. A. Kuo, and N.A. Terrault Is recurrent hepatitis C worse with living donors? Curr Opin Organ Transplant 14 3 2009 240
2. K. Watt, B. Veldt, and M. Charlton A practical guide to the management of HCV infection following liver transplantation Am J Transplant 9 8 2009 1707
3. M. Berenguer Natural history of recurrent hepatitis C Liver Transpl 8 10 suppl 1 2002 S14
4. E. Melum, S. Friman, and K. Bjoro Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma J Hepatol 47 6 2007 777
5. E.J. Gane The natural history of recurrent hepatitis C and what influences this Liver Transpl 14 suppl 2 2008 S36
6. N. Selzner, E.L. Renner, and M. Selzner Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome Transplantation 88 10 2009 1214
7. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2 2008 274
8. R. Bataller, P. Gines, and J.M. Nicolas Angiotensin II induces contraction and proliferation of human hepatic stellate cells Gastroenterology 118 6 2000 1149
9. J.S. Lubel, C.B. Herath, L.M. Burrell, and P.W. Angus Liver disease and the renin-angiotensin system: recent discoveries and clinical implications J Gastroenterol Hepatol 23 9 2008 1327
10. H. Yoshiji, S. Kuriyama, and H. Fukui Blockade of renin-angiotensin system in antifibrotic therapy J Gastroenterol Hepatol 22 suppl 1 2007 S93
11. J. Liu, H. Gong, Z.T. Zhang, and Y. Wang Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells Chin Med J (Engl) 121 2 2008 161
12. H. Yoshiji, S. Kuriyama, and J. Yoshii Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats Hepatology 34 4 pt 1 2001 745
13. J.E. Toblli, M.C. Munoz, G. Cao, J. Mella, L. Pereyra, and R. Mastai ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats Obesity (Silver Spring) 16 4 2008 770
14. S. Yokohama, Y. Tokusashi, and K. Nakamura Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis World J Gastroenterol 12 2 2006 322
15. Y. Terui, T. Saito, and H. Watanabe Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C Hepatology 36 4 pt 1 2002 1022
16. S. Sookoian, M.A. Fernandez, and G. Castano Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study World J Gastroenterol 11 48 2005 7560
17. A. Rimola, M.C. Londono, and G. Guevara Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation Transplantation 78 5 2004 686
18. M. Berenguer, M. Prieto, and F. San Juan Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients Hepatology 36 1 2002 202
19. N. Selzner, N. Girgrah, and L. Lilly The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age Liver Transpl 14 12 2008 1778
20. V.I. Machicao, H. Bonatti, and M. Krishna Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C Transplantation 77 1 2004 84
21. M. Wali, R.F. Harrison, P.J. Gow, and D. Mutimer Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C Gut 51 2 2002 248
22. K.W. Burak, W.K. Kremers, and K.P. Batts Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C Liver Transpl 8 4 2002 362
23. J.R. Lake The role of immunosuppression in recurrence of hepatitis C Liver Transpl 9 11 2003 S63
24. M. Berenguer What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 42 4 2005 448
25. G.W. McCaughan, and A. Zekry Mechanisms of HCV reinfection and allograft damage after liver transplantation J Hepatol 40 3 2004 368
26. J.R. Jonsson, A.D. Clouston, and Y. Ando Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis Gastroenterology 121 1 2001 148
27. N. Kurikawa, M. Suga, S. Kuroda, K. Yamada, and H. Ishikawa An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells Br J Pharmacol 139 6 2003 1085
28. H.S. Wei, D.G. Li, and H.M. Lu Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4) World J Gastroenterol 6 4 2000 540
29. I. Tuncer, H. Ozbek, S. Ugras, and I. Bayram Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis Exp Toxicol Pathol 55 2-3 2003 159
30. X. Li, Y. Meng, X.S. Yang, L.F. Mi, and S.X. Cai ACEI attenuates the progression of CCl4-induced rat hepatic fibrogenesis by inhibiting TGF-beta1, PDGF-BB, NF-kappaB and MMP-2,9 World J Gastroenterol 11 31 2005 4807
31. G. Paizis, R.E. Gilbert, and M.E. Cooper Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis J Hepatol 35 3 2001 376
32. H. Yoshiji, J. Yoshii, and Y. Ikenaka Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats J Hepatol 37 1 2002 22
33. M. Berenguer, L. Ferrell, and J. Watson HCV-related fibrosis progression following liver transplantation: increase in recent years J Hepatol 32 4 2000 673
34. P. Ibanez, N. Solis, and M. Pizarro Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis J Gastroenterol Hepatol 22 6 2007 846
35. A. Hirose, M. Ono, and T. Saibara Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis Hepatology 45 6 2007 1375
36. P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 24 2 1996 289